Chromatography Supplies
Agilent Technologies NEEDLE HDSPACE TRANSFER LINE
Needle, headspace transfer line, deactivated, 0.7 mm od, 0.4 mm id
Medchemexpress LLC Ac-Phe-{Orn}-Pro-{dCha}-Trp-Arg (lactam bridge: Orn2-Arg6) | 219639-75-5 | MFCD07363866 | ≥98.0% | 896.09 g·mol⁻¹ | C47H65N11O7 | 25 MG
PMX-53 is a synthetic peptidic antagonist of the complement C5a receptor (CD88) used in research to probe complement-mediated inflammation. It is orally active and inhibits C5a-induced neutrophil responses with a reported IC50 of ≈20 nM. The compound is supplied as a solid; molecular formula C47H65N11O7; molecular weight 896.09 g·mol⁻1; recommended storage at -20°C (in solvent: -80°C for long-term).
- Potent C5aR antagonist with low-nanomolar activity.
- Active in both in vitro and in vivo models.
- Peptidic structure suitable for mechanistic studies of complement signaling.
- Stable solid form with defined storage conditions.
- Available in small research pack sizes for experimental flexibility.
Loikits Distribution SYLTHERM 800-SILICONE LIQ 5GAL
Fluid, Heat Transfer Fluid; Largeoikits; For Syltherm 800; Stable; Largeong lasting silicone based product; For high temp. liquid-phase operation; Temp: of - 40 deg. to 400 deg. C; High temp. stability; Largeo
Medchemexpress LLC L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl- | 514814-49-4 | 99.5% | 839.04 | 25 MG
PMX 205 is a potent and orally active complement C5a receptor (C5aR; CD88) antagonist. This selective C5aR antagonist is supplied in solid form as a white to off-white powder.
- Potent complement C5a receptor (C5aR; CD88) antagonist
- Orally active and selective C5aR antagonist
- Showed significant results in MTT assays
- Extended survival time and reduced end-stage motor scores in a rat model of amyotrophic lateral sclerosis
- Reduced astroglial proliferation in SOD1G93A rats
- Reduced fibrillar plaque load in Tg2576 mice
- Reduced hyperphosphorylated tau (69%) in 3xTg mice
- Blocked C5a-stimulated increase in CD44 expression in PECs
- Reversed C5a-increased PEC-derived COL4A2 secretion
- Reduced C5a-increased proliferation of PECs
- Induced suppression of GPX4 expression and inhibition of tumor growth in mice